Table 3.
Biomarkers of systemic inflammation at baseline and 1 year, by n-3 FA randomization.
| Active n-3 FA, n = 784 | Placebo n-3 FA, n = 777 | Overall percent change active/placebo n-3 FA (95% CI) | P unadjusted modela | P adjusted modelb | |
|---|---|---|---|---|---|
| Baseline ln (IL-6) pg/mL, geometric mean (95% CI) | 1.69 (1.63–1.75) | 1.70 (1.63–1.77) | |||
| Year 1 ln (IL-6) pg/mL, geometric mean (95% CI) | 1.70 (1.64–1.77) | 1.72 (1.66–1.79) | |||
| Percent change from baseline (95% CI) | 0.67% (−3.76 to 5.31) | 1.41% (−3.07 to 6.10) | −0.73% (−6.87 to 5.81) | 0.82 | 0.97 |
| Baseline ln (TNFR2) pg/mL, geometric mean (95% CI) | 2571.3 (2528.1–2615.2) | 2500.9 (2463.6–2538.8) | |||
| Year 1 ln (TNFR2) pg/mL, geometric mean (95% CI) | 2605.3 (2561.4–2649.9) | 2567.3 (2527.7–2607.6) | |||
| Percent change from baseline (95% CI) | 1.35% (0.17–2.55) | 2.66% (1.46–3.87) | −1.27% (−2.89 to 0.39) | 0.13 | 0.13 |
| Baseline ln (hsCRP) mg/L, geometric mean (95% CI) | 1.57 (1.49–1.66) | 1.43 (1.35–1.51) | |||
| Year 1 ln (hsCRP) mg/L, geometric mean (95% CI) | 1.63 (1.54–1.72) | 1.53 (1.45–1.62) | |||
| Percent change from baseline (95% CI) | 3.70% (−2.49 to 10.27) | 7.90% (1.44–14.77) | −3.89% (−11.92 to 4.86) | 0.37 | 0.44 |
a
Linear models comparing natural logarithm of biomarker concentration in active vs placebo n-3 FA groups.
b
Linear models comparing natural logarithm of biomarker concentration in active n-3 FA vs placebo n-3 FA groups, adjusted for age, sex, race, and vitamin D randomized treatment group.